ATLANTA, May 6, 2016 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
The seven Alimera data presentations at ARVO were as follows:
- Clinical Effectiveness of the Fluocinolone Acetonide Implant in Diabetic Macular Oedema Resistant to Anti-VEGF Therapy, authored by Spyridon Chalkiadakis, Fiona Harris and Simon Taylor, University of Surrey, and Royal Surrey County Hospital, Guildford, U.K.
- Short-term Results of Fluocinolone Acetonide Intravitreal Implant (ILUVIEN®) for Diabetic Macular Edema in Highly Treated Eyes, authored by Nisha Dhawlikar, Sumit P. Shah , David L. Yarian, Jonathan L. Prenner , Eric S. Friedman, Howard F. Fine, H. M. Wheatley, and Daniel B. Roth, Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, and N.J. Retina, New Brunswick, New Jersey.
- Preliminary Results from the RESPOND Trial: Investigator-driven Study in Portugal to Evaluate Real-life Safety and Efficacy of ILUVIEN in Patients with Chronic DME, authored by Joao Figueira, Miguel Amaro, José Henriques and Vitor Rosas, CEC, AIBILI, Coimbra, Portugal, Coimbra University Hospital, Coimbra, Portugal, Hosptial Vila Franca de Xira, Vila Franca de Xira, Portugal, Instituto de Retina e Diabetes Ocular de Lisboa, Lisboa Portugal, Centro Hospitalar de São João, Porto, Portugal.
- Change in Retinal Function and Morphology in Patients with Diabetic Macular Edema Switching from Anti-VEGF to Steroid (Fluocinolone Acetonide), authored by Radha Das and Usha Chakravarthy, School of Medicine, Queens University, Belfast, U.K.
- A Retrospective Evaluation of the Efficacy and Safety of Fluocinolone Acetonide 0.2 Microgram Implant in Patients with Chronic Diabetic Macular Edema with Insufficient Response to Other Therapies, authored by Angelina Meireles, João Coelho, and Bernardete Pessoa, Centro Hospitalar do Porto-HSA, Porto, Portugal, and Medicine Faculty, Abel Salazar Biomedical Sciences Institute, Porto, Portugal.
- The Outcome of Chronic Diabetic Macular Oedema in Patients Treated with Intravitreal Fluocinolone Acetonide (ILUVIEN), authored by Ibraheem El-Ghrably, James Cook University Hospital, Newcastle Upon-Tyne, U.K.
- Sustained Intraocular Delivery of Fluocinolone Acetonide Slows Progression of Diabetic Retinopathy, authored by Peter A. Campochiaro, Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, Charles C. Wykoff, Retina Consultants of Houston, Houston, Texas, and Barry Kapik and Ken E. Green, Alimera Sciences, Inc.
ILUVIEN'S U.S. Indication
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide, a corticosteroid, for 36 months.
ILUVIEN'S E.U. Indication
ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME. All people with type 1 or type 2 diabetes are at risk of developing DME. As the population of people with diabetes increases, Alimera expects the annual incidence of diagnosed DME to increase, as well.
In the United Kingdom and parts of Europe, diabetic macular edema is instead referred to as diabetic macular oedema or DMO.
About Alimera Sciences, Inc.
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alimera-sciences-iluvien-data-presented-at-2016-arvo-300264201.html
SOURCE Alimera Sciences, Inc.